<SEC-DOCUMENT>0001193125-20-195481.txt : 20200720
<SEC-HEADER>0001193125-20-195481.hdr.sgml : 20200720
<ACCEPTANCE-DATETIME>20200720161535
ACCESSION NUMBER:		0001193125-20-195481
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20200720
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200720
DATE AS OF CHANGE:		20200720

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ACADIA PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001070494
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				061376651
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50768
		FILM NUMBER:		201036596

	BUSINESS ADDRESS:	
		STREET 1:		3611 VALLEY CENTRE DRIVE
		STREET 2:		SUITE 300
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		858-558-2871

	MAIL ADDRESS:	
		STREET 1:		3611 VALLEY CENTRE DRIVE
		STREET 2:		SUITE 300
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d120197d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:acad="http://www.acadia-pharm.com/20200720" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body>
 <div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityRegistrantName" name="dei:EntityRegistrantName" contextRef="duration_2020-07-20_to_2020-07-20">ACADIA PHARMACEUTICALS INC</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2020-07-20_to_2020-07-20">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2020-07-20_to_2020-07-20">0001070494</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="acad-20200720.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2020-07-20_to_2020-07-20"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001070494</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-20</xbrli:startDate> <xbrli:endDate>2020-07-20</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:11pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:11pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2020-07-20_to_2020-07-20">8-K</ix:nonNumeric></p> <p style="font-size:11pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:11pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:11pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2020-07-20_to_2020-07-20" format="ixt:datemonthdayyearen">July 20, 2020</ix:nonNumeric></p> <p style="font-size:11pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:11pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <span style=" -sec-ix-hidden:Hidden_dei_EntityRegistrantName">ACADIA Pharmaceuticals Inc.</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:11pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:11pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2020-07-20_to_2020-07-20" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2020-07-20_to_2020-07-20">000-50768</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2020-07-20_to_2020-07-20">06-1376651</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(State or other jurisdiction of<br />incorporation or organization)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Commission<br />File Number)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(IRS Employer<br />Identification No.)</span></td></tr></table> <p style="font-size:11pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top" colspan="3"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2020-07-20_to_2020-07-20">3611 Valley Centre Drive</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2020-07-20_to_2020-07-20">Suite 300</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2020-07-20_to_2020-07-20">San Diego</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2020-07-20_to_2020-07-20" format="ixt-sec:stateprovnameen">California</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2020-07-20_to_2020-07-20">92130</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top" colspan="3"><span style="font-weight:bold">(Address of principal executive offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:11pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2020-07-20_to_2020-07-20">(858)</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2020-07-20_to_2020-07-20">558-2871</ix:nonNumeric></p> <p style="margin-top:11pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">N/A</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report.)</p> <p style="font-size:11pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:11pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. of Form <span style="white-space:nowrap">8-K):</span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2020-07-20_to_2020-07-20" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2020-07-20_to_2020-07-20" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2020-07-20_to_2020-07-20" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2020-07-20_to_2020-07-20" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table> <p style="margin-top:11pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section 12(b) of the Act:</p> <p style="font-size:11pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br />Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br />on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2020-07-20_to_2020-07-20">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2020-07-20_to_2020-07-20">ACAD</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2020-07-20_to_2020-07-20" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table> <p style="margin-top:11pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#160;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</p> <p style="margin-top:11pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2020-07-20_to_2020-07-20" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:11pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item 8.01 Other Events. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(a)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">On July&#160;20, 2020, ACADIA Pharmaceuticals Inc. (the &#8220;Company&#8221;) announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its supplemental New Drug Application (sNDA) for NUPLAZID<sup style="font-size:85%; vertical-align:top">&#174;</sup> (pimavanserin) for the treatment of hallucinations and delusions associated with dementia-related psychosis (DRP). </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The FDA has assigned a standard review with a PDUFA (Prescription Drug User Fee Act) action date of April&#160;3, 2021. The FDA has also informed the Company that it has not identified any potential review issues at this point in their evaluation and at this time they are not planning to hold an Advisory Committee meeting. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The sNDA is supported by results from the pivotal Phase 3 HARMONY study, which met its primary endpoint, demonstrating that pimavanserin significantly reduced the risk of relapse of psychosis by 2.8 fold compared to placebo (hazard ratio = 0.353; <span style="white-space:nowrap">one-sided</span> p=0.0023). The sNDA also includes positive efficacy results from two additional placebo-controlled studies, both of which met their respective primary endpoints: The Phase 2 <span style="white-space:nowrap">(-019)</span> study in patients with Alzheimer&#8217;s disease psychosis and the Phase 3 <span style="white-space:nowrap">(-020)</span> study in patients with Parkinson&#8217;s disease psychosis. The sNDA includes a large safety database from completed and ongoing studies representing over 1500 patients with neurodegenerative disease. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(b)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Also on July&#160;20, 2020, the Company announced <span style="white-space:nowrap">top-line</span> results from its 298 patient Phase 3 CLARITY study which combined two identical, double-blind, placebo-controlled studies evaluating the efficacy, safety and tolerability of pimavanserin as an adjunctive treatment for major depressive disorder (MDD). The combined efficacy and safety analysis was <span style="white-space:nowrap">pre-specified</span> prior to data unblinding following feedback from the FDA. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The study did not achieve statistical significance on the primary endpoint which was the <span style="white-space:nowrap">17-item</span> Hamilton Depression Rating Scale <span style="white-space:nowrap">(HAMD-17)</span> total score change from baseline to week 5. Pimavanserin 34 mg, given once-daily as an adjunctive treatment to standard antidepressant therapy was associated with a mean reduction of 9.0 in <span style="white-space:nowrap">HAMD-17</span> total score compared to 8.1 for placebo as an adjunctive treatment (p=0.296). </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Positive results were observed on the key secondary endpoint, the Clinical Global Impression &#8211; Severity <span style="white-space:nowrap">(CGI-S)</span> score, a clinician assessment of a patient&#8217;s severity of depression (nominal p=0.042). In the study, pimavanserin was generally well-tolerated when added to existing antidepressant therapy, and similar rates of adverse events were observed between pimavanserin (58.1%) and placebo (54.7%). </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Phase 3 CLARITY study is a combination of <span style="white-space:nowrap">CLARITY-2</span> and <span style="white-space:nowrap">CLARITY-3,</span> which were both <span style="white-space:nowrap">6-week,</span> parallel-designed, randomized, double-blind, placebo-controlled, multi-center studies designed to evaluate the efficacy and safety of pimavanserin as adjunctive treatment in patients with MDD who have an inadequate response to standard antidepressant therapy with either a selective serotonin reuptake inhibitor (SSRI) or a serotonin norepinephrine reuptake inhibitor (SNRI). A total of 298 patients were randomized to receive six weeks of oral treatment with either 34 mg of pimavanserin or placebo, once daily, in addition to their ongoing antidepressant. The primary endpoint was change from baseline on the <span style="white-space:nowrap">HAMD-17</span> total score. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Copies of ACADIA&#8217;s press releases issued July&#160;20, 2020 are furnished herewith as Exhibits 99.1 and 99.2. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Forward-Looking Statements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Statements in this Current Report that are not strictly historical in nature are forward-looking statements. These statements include, but are not limited to, statements related to the potential benefits of pimavanserin as adjunctive treatment for major depressive disorder, the hallucinations and delusions associated with dementia-related psychosis or other central nervous system disorders, the potential results of clinical trials of pimavanserin in other indications, and the expected growth in patients with dementia. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug development, approval and commercialization, and the fact that past results of clinical trials may not be indicative of future trial results. For a discussion of these and other factors, please refer to ACADIA&#8217;s annual report on Form <span style="white-space:nowrap">10-K</span> for the year ended December&#160;31, 2019 as well as ACADIA&#8217;s subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and ACADIA undertakes no obligation to revise or update this Current Report to reflect events or circumstances after the date hereof, except as required by law. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;9.01 Financial Statements and Exhibits. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) <span style="text-decoration:underline">Exhibits</span> </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td style="width:94%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d120197dex991.htm">Press release dated July&#160;20, 2020, &#8220;ACADIA Announces U.S. FDA Accepted for Filing the Supplemental New Drug Application for NUPLAZID&#174; (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis&#8221; </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d120197dex992.htm">Press release dated July&#160;20, 2020, &#8220;ACADIA Pharmaceuticals Announces <span style="white-space:nowrap">Top-line</span> Results from the Phase 3 CLARITY Study Evaluating Pimavanserin for the Adjunctive Treatment of Major Depressive Disorder&#8221; </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">The cover page from this Current Report on Form <span style="white-space:nowrap">8-K,</span> formatted in Inline XBRL</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:44%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:5%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:44%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Date: July&#160;20, 2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">ACADIA Pharmaceuticals Inc.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td rowspan="3" style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Austin D. Kim</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Austin D. Kim</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Executive Vice President, General Counsel&#160;&amp; Secretary</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d120197dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT 99.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACADIA Announces U.S. FDA Accepted for Filing the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Supplemental New Drug Application for NUPLAZID&reg;&nbsp;(pimavanserin) for the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>- If approved, NUPLAZID would be the first and only treatment indicated for </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>dementia-related psychosis </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>- Prescription Drug User Fee Act (PDUFA) date set for April&nbsp;3, 2021 </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>- Conference call and webcast to be held today at 4:30 p.m. Eastern Time </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SAN DIEGO &#150; July</B><B></B><B>&nbsp;20, 2020 &#150; </B>ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug
Administration (FDA) has accepted for filing its supplemental New Drug Application (sNDA) for NUPLAZID<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (pimavanserin) for the treatment of hallucinations and delusions associated with
dementia-related psychosis (DRP). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are pleased that the FDA has accepted our sNDA for filing and we will be working closely with the FDA to
facilitate completion of the review in a timely manner,&#148; said Steve Davis, ACADIA&#146;s Chief Executive Officer. &#147;If approved, NUPLAZID would be the first therapy indicated for the treatment of hallucinations and delusions associated with
dementia-related psychosis. We look forward to potentially bringing this important treatment advancement to patients, caregivers and physicians.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA has assigned a standard review with a PDUFA (Prescription Drug User Fee Act) action date of April&nbsp;3, 2021. The FDA has also informed the company
that it has not identified any potential review issues at this point in their evaluation and at this time they are not planning to hold an Advisory Committee meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dementia is highly prevalent, affecting approximately 8&nbsp;million people in the U.S., and is expected to grow as the population ages. Approximately
30&nbsp;percent, or 2.4&nbsp;million people, experience dementia-related psychosis and only half of them, or 1.2&nbsp;million, are diagnosed and treated<SUP STYLE="font-size:85%; vertical-align:top">1,2</SUP>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The sNDA is supported by results from the pivotal Phase 3 HARMONY study, which met its primary endpoint, demonstrating that pimavanserin significantly reduced
the risk of relapse of psychosis by 2.8 fold compared to placebo (hazard ratio = 0.353; <FONT STYLE="white-space:nowrap">one-sided</FONT> p=0.0023). The sNDA also includes positive efficacy results from two additional placebo-controlled studies,
both of which met their respective primary endpoints: The <FONT STYLE="white-space:nowrap">Phase&nbsp;2&nbsp;(-019)</FONT> study in patients with Alzheimer&#146;s disease psychosis and the
<FONT STYLE="white-space:nowrap">Phase&nbsp;3&nbsp;(-020)</FONT> study in patients with Parkinson&#146;s disease psychosis. The sNDA includes a large safety database from completed and ongoing studies representing over 1500 patients with
neurodegenerative disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NUPLAZID was approved in the U.S. in 2016 as the first and only treatment for hallucinations and delusions associated with
Parkinson&#146;s disease psychosis. Pimavanserin was granted Breakthrough Therapy Designation by the FDA for the treatment of hallucinations and delusions associated with DRP in October 2017. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Conference Call and Webcast Information </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACADIA will provide a corporate update via conference call and webcast today at 4:30 p.m. Eastern Time. The conference call can be accessed by dialing <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">855-638-4820</FONT></FONT> for participants in the U.S. or Canada and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">443-877-4067</FONT></FONT> for international callers
(reference passcode 1486597). A telephone replay of the conference call may be accessed through July&nbsp;27, 2020 by dialing <FONT STYLE="white-space:nowrap">855-</FONT> <FONT STYLE="white-space:nowrap">859-2056</FONT> for callers in the U.S. or
Canada and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">404-537-3406</FONT></FONT> for international callers (reference passcode 1486597). The conference call will also be webcast live on ACADIA&#146;s website,
www.acadia-pharm.com, in the investors section and will be archived there until August&nbsp;20, 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>About HARMONY </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HARMONY was a Phase 3 study designed to evaluate the efficacy and safety of pimavanserin for the treatment of hallucinations and delusions associated with
dementia-related psychosis across a broad population of patients with the most common clinically diagnosed subtypes of dementia including: Alzheimer&#146;s disease, dementia with Lewy bodies, Parkinson&#146;s disease dementia, vascular dementia, and
frontotemporal dementia spectrum disorders. A total of 392 patients were enrolled in the study, with an average age of 74.5 years and a mean Mini-Mental State Examination (MMSE) score of 16.7. The primary endpoint in the study was time to relapse in
the double-blind period as represented by the Kaplan-Meier curve and the hazard ratio. <FONT STYLE="white-space:nowrap">Top-line</FONT> results were presented at the Clinical Trials on Alzheimer&#146;s Disease (CTAD) Meeting in December 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The HARMONY study included a <FONT STYLE="white-space:nowrap">12-week</FONT> open-label stabilization period during which patients with dementia-related
psychosis began treatment with pimavanserin 34 mg once daily. In the open-label period, a significant majority (61.8%) of eligible subjects (N=351) met the sustained treatment response criteria at Week 8 and Week 12 and entered the double-blind
period. Following the open-label period, patients who met <FONT STYLE="white-space:nowrap">pre-specified</FONT> criteria for treatment response were then randomized into the double-blind period of the study to continue their pimavanserin dose (34 mg
or 20 mg per day) or switched to placebo and followed for up to 26 weeks or until a relapse of psychosis occurred. Pimavanserin met its primary endpoint and was stopped at the <FONT STYLE="white-space:nowrap">pre-planned</FONT> interim analysis for
positive efficacy, demonstrating that pimavanserin significantly reduced the risk of relapse of psychosis by 2.8 fold compared to placebo (hazard ratio = 0.353; <FONT STYLE="white-space:nowrap">one-sided</FONT> p=0.0023). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pimavanserin was well-tolerated over the entire nine-month study duration, and pimavanserin treatment was not associated with a decline in cognition, as
measured by the MMSE score, or the onset or worsening of extrapyramidal symptoms, as measured by the Extrapyramidal Symptom Rating Scale A <FONT STYLE="white-space:nowrap">(ESRS-A)</FONT> score, compared to placebo. In the double-blind period, low
rates of adverse events were observed, 41.0% of patients on pimavanserin and 36.6% on placebo. Discontinuations in the double-blind period due to adverse events were low, 2.9% for pimavanserin and 3.6% for placebo. Rates of serious adverse events
were also low, 4.8% in the pimavanserin group and 3.6% in the placebo group. One death was reported in the open-label period and one death was reported in the pimavanserin group during the double-blind period. Investigators determined neither death
was related to the study drug. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>About Dementia-Related Psychosis </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approximately 8&nbsp;million people in the United States are living with dementia, a condition with a core feature of declining cognition (changes in memory,
decision-making abilities, language, etc.) resulting in functional impairment. Dementia is a manifestation of an underlying condition which is often progressive and neurodegenerative in nature.<SUP STYLE="font-size:85%; vertical-align:top">3</SUP>
In addition to cognitive decline, dementing illnesses almost universally lead to neuropsychiatric symptoms, including hallucinations, delusions, and changes in behavior. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is estimated that 2.4&nbsp;million Americans (or 30% of people with dementia) experience dementia-related hallucinations and delusions<SUP
STYLE="font-size:85%; vertical-align:top">1,2</SUP>. These symptoms may be frequent and severe and may recur over time. A hallucination is defined as a perception-like experience that occurs without an external stimulus and is sensory (seen, heard,
felt, tasted, sensed) in nature. A delusion is defined as a false, fixed belief that is resolutely held despite evidence to the contrary. Dementia-related psychosis occurs in many types of dementia, including Alzheimer&#146;s disease, dementia with
Lewy bodies, Parkinson&#146;s disease dementia, vascular dementia, and frontotemporal dementia. Serious consequences have been associated with psychosis in patients with dementia, such as repeated hospital admissions, increased likelihood of nursing
home placement, faster progression of dementia, and increased risk of morbidity and mortality<SUP STYLE="font-size:85%; vertical-align:top">4</SUP>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>About Pimavanserin </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pimavanserin is a selective serotonin
inverse agonist and antagonist preferentially targeting <FONT STYLE="white-space:nowrap">5-HT</FONT><SUB STYLE="font-size:85%; vertical-align:bottom">2A</SUB>&nbsp;receptors. These receptors are thought to play an important role in neuropsychiatric
disorders. In vitro, pimavanserin demonstrated no appreciable binding affinity for dopamine (including D2), histamine, muscarinic, or adrenergic receptors. Pimavanserin was approved for the treatment of hallucinations and delusions associated with
Parkinson&#146;s disease psychosis by the U.S. Food and Drug Administration in April 2016 under the trade name NUPLAZID<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. ACADIA submitted a supplemental new drug application (sNDA) for
pimavanserin for the treatment of hallucinations and delusions associated with dementia-related psychosis on June&nbsp;3, 2020. The FDA has accepted for filing the sNDA for DRP with a PDUFA date of April&nbsp;3, 2021. NUPLAZID is not approved for
dementia-related psychosis. In addition, ACADIA is developing pimavanserin in other neuropsychiatric conditions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>About ACADIA Pharmaceuticals </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central
nervous system disorders. ACADIA has developed and commercialized the first and only medicine approved for the treatment of hallucinations and delusions associated with Parkinson&#146;s disease psychosis. ACADIA&#146;s development efforts are
focused on pimavanserin for additional neuropsychiatric conditions, trofinetide for Rett syndrome, and an early-stage muscarinic receptor program. This press release and further information about ACADIA can be found at: <U>www.acadia-pharm.com</U>.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Forward-Looking Statements </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Statements in this press
release that are not strictly historical in nature are forward-looking statements. These statements include, but are not limited to, statements related to pimavanserin as a potential treatment for the hallucinations and delusions associated with
dementia-related psychosis, the expected growth in patients with dementia and other statements that are not </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
historical facts. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ
materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug development, and approval and commercialization. For a discussion of these and other factors, please refer to
ACADIA&#146;s annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2019 as well as ACADIA&#146;s subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in
their entirety by this cautionary statement and ACADIA undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Important Safety Information and Indication for NUPLAZID (pimavanserin) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indication </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NUPLAZID is indicated for the treatment of
hallucinations and delusions associated with Parkinson&#146;s disease psychosis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Important Safety Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of
death. </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>NUPLAZID is not approved for the treatment of patients with dementia-related psychosis unrelated to the
hallucinations and delusions associated with Parkinson&#146;s disease psychosis. </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Contraindication:</B> NUPLAZID is contraindicated in patients with a history of a hypersensitivity reaction to
pimavanserin or any of its components. Rash, urticaria, and reactions consistent with angioedema (e.g., tongue swelling, circumoral edema, throat tightness, and dyspnea) have been reported. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Warnings and Precautions: </B>QT Interval Prolongation </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">NUPLAZID prolongs the QT interval. The use of NUPLAZID should be avoided in patients with known QT prolongation
or in combination with other drugs known to prolong QT interval including Class&nbsp;1A antiarrhythmics or Class&nbsp;3 antiarrhythmics, certain antipsychotic medications, and certain antibiotics. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">NUPLAZID should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances
that may increase the risk of the occurrence of torsade de pointes and/or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and presence of congenital prolongation of the QT interval. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Adverse Reactions: </B>The<B> </B>common adverse reactions<B>
</B>(<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>2% for NUPLAZID and greater than placebo) were<B> </B>peripheral edema (7% vs 2%), nausea (7% vs 4%), confusional state (6% vs 3%), hallucination (5% vs 3%), constipation (4% vs 3%), and gait
disturbance (2% vs &lt;1%). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Drug Interactions: </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Coadministration with strong CYP3A4 inhibitors (e.g., ketoconazole) increases NUPLAZID exposure. Reduce NUPLAZID
dose to 10 mg taken orally as one tablet once daily. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Coadministration with strong or moderate CYP3A4 inducers reduces NUPLAZID exposure. Avoid concomitant use of
strong or moderate CYP3A4 inducers with NUPLAZID. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dosage and Administration </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Recommended dose: 34 mg capsule taken orally once daily, without titration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NUPLAZID is available as 34 mg capsules and 10 mg tablets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please read the full <U>Prescribing Information</U> including <B>Boxed WARNING</B>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>References </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Plassman BL, et al. Prevalence of dementia in the United States: The Aging Demographics, and Memory study.
<I>Neuroepidemiology</I>. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2007;29(1-2):125-132.</FONT></FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">2017 Alzheimer&#146;s Disease Facts and Figures and ACADIA market research. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dementia. (2019, September 19). Retrieved from
<U>https://www.who.int/news-room/fact-sheets/detail/dementia</U>. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">4</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Connors MH et al. <I>Am J Geriatr Psychiatry</I> 2018;26(3). Peters ME et al. <I>Am J Psychiatry</I>
2015;172(5). Haupt M et al. <I>Int J Geriatr Psychiatry</I> 1996;11(11). Naimark D et al. <I>J Am Geriatr</I> Soc 1996;44(3). Stern Y et al. <I>Neurology </I>1994;44(12). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Media Contact: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACADIA Pharmaceuticals Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stephanie Fagan </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(858)
<FONT STYLE="white-space:nowrap">212-0534</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">media@acadia-pharm.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investor Contact: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACADIA Pharmaceuticals Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mark Johnson, CFA </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(858)
<FONT STYLE="white-space:nowrap">261-2771</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ir@acadia-pharm.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d120197dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT 99.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACADIA Pharmaceuticals Announces <FONT STYLE="white-space:nowrap">Top-line</FONT> Results from the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Phase 3 CLARITY Study Evaluating Pimavanserin for the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Adjunctive Treatment of Major Depressive Disorder </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>- The study did not achieve statistical significance on the primary endpoint </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>- Conference call and webcast to be held today at 4:30 p.m. Eastern Time </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SAN DIEGO, CA, </B><B>July</B><B></B><B>&nbsp;20, 2020</B> &#150; ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced
<FONT STYLE="white-space:nowrap">top-line</FONT> results from its 298 patient Phase&nbsp;3 CLARITY study which combined two identical, double-blind, placebo-controlled studies evaluating the efficacy, safety and tolerability of pimavanserin as an
adjunctive treatment for major depressive disorder (MDD). The combined efficacy and safety analysis was <FONT STYLE="white-space:nowrap">pre-specified</FONT> prior to data unblinding following feedback from the FDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The study did not achieve statistical significance on the primary endpoint which was the <FONT STYLE="white-space:nowrap">17-item</FONT> Hamilton Depression
Rating Scale <FONT STYLE="white-space:nowrap">(HAMD-17)</FONT> total score change from baseline to week 5. Pimavanserin 34 mg, given once-daily as an adjunctive treatment to standard antidepressant therapy was associated with a mean reduction of 9.0
in <FONT STYLE="white-space:nowrap">HAMD-17</FONT> total score compared to 8.1 for placebo as an adjunctive treatment (p=0.296). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Positive results were
observed on the key secondary endpoint, the Clinical Global Impression &#150; Severity <FONT STYLE="white-space:nowrap">(CGI-S)</FONT> score, a clinician assessment of a patient&#146;s severity of depression (nominal p=0.042). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We observed a consistent improvement of depressive symptoms over time with pimavanserin but, unfortunately, the robust positive results from our <FONT
STYLE="white-space:nowrap">CLARITY-1</FONT> study were not replicated,&#148; said Serge Stankovic, ACADIA&#146;s President. &#147;While these results do not support the product profile to pursue a broad adjunctive MDD indication, we will continue to
analyze the data and the findings from our earlier positive depression studies as we assess next steps. All of us at ACADIA thank the patients, their families and the investigators who participated in the Phase 3 CLARITY study.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the study, pimavanserin was generally well-tolerated when added to existing antidepressant therapy, and similar rates of adverse events were observed
between pimavanserin (58.1%) and placebo (54.7%). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>About the Phase 3 CLARITY Study </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Phase 3 CLARITY study is a combination of <FONT STYLE="white-space:nowrap">CLARITY-2</FONT> and <FONT STYLE="white-space:nowrap">CLARITY-3,</FONT> which
were both <FONT STYLE="white-space:nowrap">6-week,</FONT> parallel-designed, randomized, double-blind, placebo-controlled, multi-center studies designed to evaluate the efficacy and safety of pimavanserin as adjunctive treatment in patients with MDD
who have an inadequate response to standard antidepressant therapy with either a selective serotonin reuptake inhibitor (SSRI) or a serotonin norepinephrine reuptake inhibitor (SNRI). A total of 298 patients were randomized to receive six weeks of
oral treatment with either 34 mg of pimavanserin or placebo, once daily, in addition to their ongoing antidepressant. The primary endpoint was change from baseline on the <FONT STYLE="white-space:nowrap">HAMD-17</FONT> total score. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Phase 3 CLARITY Study Results: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efficacy Analysis </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Statistical significance not achieved on the primary endpoint: <FONT STYLE="white-space:nowrap">HAMD-17</FONT>
(p=0.296). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Positive results observed on key secondary endpoint: <FONT STYLE="white-space:nowrap">CGI-S</FONT> (nominal
p=0.042). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Positive results observed on Karolinska Sleepiness Scale (KSS) score (nominal p=0.005). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Clinically meaningful separation was not achieved on the other secondary endpoints. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Safety and Tolerability </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Similar rates of adverse events were observed between pimavanserin (58.1%) and placebo (54.7%).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Adverse events reported in greater than 5% of patients on pimavanserin and greater than placebo were diarrhea,
dry mouth and headache. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Discontinuations due to adverse events were 2.7% for both pimavanserin and placebo. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Two subjects in each of the pimavanserin and placebo groups reported serious adverse events (SAEs). These SAEs
were deemed not to be related to the study drug by the investigators. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The adjunctive use of pimavanserin did not result in clinically significant differences in vital signs, metabolic
parameters or extrapyramidal symptoms compared to placebo. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACADIA previously announced <U>plans</U> to combine its <FONT
STYLE="white-space:nowrap">CLARITY-2</FONT> and <FONT STYLE="white-space:nowrap">CLARITY-3</FONT> Phase 3 studies evaluating pimavanserin for the adjunctive treatment of MDD with a <FONT STYLE="white-space:nowrap">pre-specified</FONT> statistical
analysis plan. The two Phase 3 studies concluded with slightly more than 50% enrollment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patients who completed the Phase 3 study were eligible to
participate in the ongoing <FONT STYLE="white-space:nowrap">52-week</FONT> open-label extension study to evaluate the long-term safety and tolerability of pimavanserin as adjunctive treatment to standard antidepressants in MDD. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>About the <FONT STYLE="white-space:nowrap">CLARITY-1</FONT> Study </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">CLARITY-1</FONT> was a Phase 2, <FONT STYLE="white-space:nowrap">10-week,</FONT> randomized, double-blind, placebo-controlled,
multi-center, <FONT STYLE="white-space:nowrap">2-stage</FONT> sequential parallel comparison design (SPCD) study that evaluated the safety, tolerability, and efficacy of pimavanserin (34 mg once daily) as an adjunctive treatment in patients with MDD
who had an inadequate response to a stable dose of standard antidepressant therapy with either a SSRI or a SNRI. The study was conducted in collaboration with the Massachusetts General Hospital Clinical Trials Network&nbsp;&amp; Institute and
randomized 207 patients across 27 clinical research centers in the U.S. and was completed in 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the trial, pimavanserin met the primary endpoint by
significantly reducing the <FONT STYLE="white-space:nowrap">HAMD-17</FONT> total score compared to placebo (p=0.039). On the key secondary endpoint, pimavanserin demonstrated statistically significant reductions compared to placebo in the Sheehan
Disability Scale score (p=0.004). Positive results were also observed for seven other secondary endpoints including the <FONT STYLE="white-space:nowrap">CGI-S</FONT> score (p=0.008) and the KSS score (p=0.021). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the parallel design portion (Stage 1) of this SPCD study, adding pimavanserin to SSRI or SNRI therapy also significantly reduced <FONT
STYLE="white-space:nowrap">HAMD-17</FONT> scores compared to placebo (p=0.0003). On the key secondary endpoint, pimavanserin also demonstrated statistically significant reductions compared to placebo in the Sheehan Disability Scale score (p=0.004).
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>About the Open-Label Comorbid Parkinson&#146;s Disease and Depression Study </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This was an <FONT STYLE="white-space:nowrap">8-week,</FONT> open-label, <FONT STYLE="white-space:nowrap">single-arm</FONT> Phase 2 study evaluating the
efficacy and safety of pimavanserin as an adjunct to a SSRI or a SNRI or as a monotherapy in adults with both Parkinson&#146;s disease and depression (n=47) and was completed in 2019. In the study, patients treated with pimavanserin had significant
improvement on the primary endpoint, the <FONT STYLE="white-space:nowrap">HAMD-17</FONT> total score change in baseline to week 8 (p&lt;0.0001), with significant improvement seen as early as week 2 (p&lt;0.0001). Improvement of <FONT
STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>50% on the <FONT STYLE="white-space:nowrap">HAMD-17</FONT> total score was observed in 60.0% of patients at week 8, with 44.4% of patients reaching remission <FONT STYLE="white-space:nowrap">(HAMD-17</FONT> <FONT
STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT>7). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional results from this study showed that Parkinson&#146;s disease patients treated with pimavanserin
for depression also demonstrated improvement on multiple secondary endpoints compared to baseline, including the <FONT STYLE="white-space:nowrap">CGI-S</FONT> score (p&lt;0.0001) and the SCOPA-Global Sleep Quality scale (p&lt;0.0001). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Conference Call and Webcast Information </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACADIA will
provide a corporate update via conference call and webcast today at 4:30 p.m. Eastern Time. The conference call can be accessed by dialing <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">855-638-4820</FONT></FONT> for participants
in the U.S. or Canada and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">443-877-4067</FONT></FONT> for international callers (reference passcode 1486597). A telephone replay of the conference call may be accessed through
July&nbsp;27, 2020 by dialing <FONT STYLE="white-space:nowrap">855-</FONT> <FONT STYLE="white-space:nowrap">859-2056</FONT> for callers in the U.S. or Canada and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">404-537-3406</FONT></FONT> for international callers (reference passcode 1486597). The conference call will also be webcast live on ACADIA&#146;s website, www.acadia-pharm.com, in the
investors section and will be archived there until August&nbsp;20, 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>About Major Depressive Disorder </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">According to the National Institute of Mental Health, MDD affects approximately 17&nbsp;million adults in the
U.S.<SUP STYLE="font-size:85%; vertical-align:top">1</SUP>, with approximately 2.5&nbsp;million adults treated with adjunctive therapy.<SUP STYLE="font-size:85%; vertical-align:top">2,3</SUP> MDD is a condition characterized by depressive symptoms
such as a depressed mood or a loss of interest or pleasure in daily activities for more than two weeks, as well as impaired social, occupational, or other important functioning. Continuing depression has been consistently linked with greater
economic burden, with higher rate of healthcare utilization and reduced work productivity.<SUP STYLE="font-size:85%; vertical-align:top">4</SUP> The majority of people who suffer from MDD do not respond adequately to initial antidepressant therapy
or discontinue due to side effects or safety concerns.<SUP STYLE="font-size:85%; vertical-align:top">5,6</SUP> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>About Pimavanserin </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pimavanserin is a selective serotonin inverse agonist and antagonist preferentially targeting <FONT STYLE="white-space:nowrap">5-HT</FONT><SUB
STYLE="font-size:85%; vertical-align:bottom">2A</SUB> receptors. The serotonin system is thought to play an important role in neuropsychiatric disorders. In vitro, pimavanserin demonstrated no appreciable binding affinity for dopamine (including
D2), histamine, muscarinic, or adrenergic receptors. Pimavanserin was approved for the treatment of hallucinations and delusions associated with Parkinson&#146;s disease psychosis by the U.S. Food and Drug Administration in April 2016 under the
trade name NUPLAZID<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. ACADIA submitted a supplemental new drug application (sNDA) for pimavanserin for the treatment of hallucinations and delusions associated with dementia-related psychosis
on June&nbsp;3, </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
2020. The FDA has accepted for filing the sNDA for DRP with a PDUFA date of April&nbsp;3, 2021. NUPLAZID is not approved for dementia-related psychosis. In addition, ACADIA is developing
pimavanserin in other neuropsychiatric conditions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>About ACADIA Pharmaceuticals </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central
nervous system disorders. ACADIA has developed and commercialized the first and only medicine approved for the treatment of hallucinations and delusions associated with Parkinson&#146;s disease psychosis. ACADIA&#146;s development efforts are
focused on pimavanserin for additional neuropsychiatric conditions, trofinetide for Rett syndrome, and an early-stage muscarinic receptor program. This press release and further information about ACADIA can be found at: <U>www.acadia-pharm.com.</U>
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Forward-Looking Statements </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Statements in this press
release that are not strictly historical in nature are forward-looking statements. These statements include, but are not limited to, statements related to the potential benefits of pimavanserin as adjunctive treatment for major depressive disorder
or other central nervous system disorders as well as the potential results of clinical trials of pimavanserin in other indications. These statements are only predictions based on current information and expectations and involve a number of risks and
uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug development, approval and commercialization, and the fact
that past results of clinical trials may not be indicative of future trial results. For a discussion of these and other factors, please refer to ACADIA&#146;s annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended
December&nbsp;31, 2019 as well as ACADIA&#146;s subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution
is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and ACADIA undertakes no obligation to revise or update
this press release to reflect events or circumstances after the date hereof, except as required by law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Important Safety Information and Indication
for NUPLAZID (pimavanserin) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indication</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>NUPLAZID is indicated for the treatment of hallucinations and delusions associated with Parkinson&#146;s disease psychosis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Important Safety Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WARNING: INCREASED
MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of
death.</B> </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>NUPLAZID is not approved for the treatment of patients with dementia-related psychosis unrelated to the
hallucinations and delusions associated with Parkinson&#146;s disease psychosis.</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Contraindication:</B> NUPLAZID is contraindicated in patients with a history of a hypersensitivity reaction to
pimavanserin or any of its components. Rash, urticaria, and reactions consistent with angioedema (e.g., tongue swelling, circumoral edema, throat tightness, and dyspnea) have been reported. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Warnings and Precautions: </B>QT Interval Prolongation </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">NUPLAZID prolongs the QT interval. The use of NUPLAZID should be avoided in patients with known QT prolongation
or in combination with other drugs known to prolong QT interval including Class&nbsp;1A antiarrhythmics or Class&nbsp;3 antiarrhythmics, certain antipsychotic medications, and certain antibiotics. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">NUPLAZID should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances
that may increase the risk of the occurrence of torsade de pointes and/or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and presence of congenital prolongation of the QT interval. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Adverse Reactions: </B>The<B> </B>common adverse reactions<B>
</B>(<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>2% for NUPLAZID and greater than placebo) were<B> </B>peripheral edema (7% vs 2%), nausea (7% vs 4%), confusional state (6% vs 3%), hallucination (5% vs 3%), constipation (4% vs 3%), and gait
disturbance (2% vs &lt;1%). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Drug Interactions</B>: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Coadministration with strong CYP3A4 inhibitors (e.g., ketoconazole) increases NUPLAZID exposure. Reduce NUPLAZID
dose to 10 mg taken orally as one tablet once daily. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Coadministration with strong or moderate CYP3A4 inducers reduces NUPLAZID exposure. Avoid concomitant use of
strong or moderate CYP3A4 inducers with NUPLAZID. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dosage and Administration</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>Recommended dose: 34 mg capsule taken orally once daily, without titration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NUPLAZID is available as 34 mg capsules and 10 mg tablets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please read the full <U>Prescribing Information</U> including <B>Boxed WARNING</B>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>References </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">National Institute of Mental Health. (2017). Major Depression. Retrieved from
http://www.nimh.nih.gov/health/statistics/major-depression.shtml </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">IMS NSP, NPA, NDTI <FONT STYLE="white-space:nowrap">MAT-24</FONT> month data through Aug 2017.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">PLOS One, Characterization of Treatment Resistant Depression Episodes in a Cohort of Patients from a US
Commercial Claims Database, Oct&nbsp;2013, Vol 8, Issue 10. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">4</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Greenberg PE, Fournier AA, Sisitsky T, Pike CT, Kessler RC. The economic burden of adults with major depressive
disorder in the United States (2005 and 2010). <I>J Clin Psych.</I> <FONT STYLE="white-space:nowrap">2015;76(2):155-162.</FONT> doi: 10.4088/JCP.14m09298. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">5</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Rush AJ, et al. (2007)<I>&nbsp;Am J. Psychiatry</I> 163:11, pp. 1905-1917 (STAR*D Study).
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">6</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Sansone RA, Sansone LA. Antidepressant adherence: are patients taking their medications? <I>Innov Clin
Neurosci</I>. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2012;9(5-6):41-46.</FONT></FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Media Contact: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACADIA Pharmaceuticals Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stephanie Fagan </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(858) <FONT STYLE="white-space:nowrap">212-0534</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">media@acadia-pharm.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investor Contact: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACADIA Pharmaceuticals Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mark Johnson, CFA </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(858) <FONT STYLE="white-space:nowrap">261-2771</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ir@acadia-pharm.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>acad-20200720.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-5 Build:20200707.2 -->
<!-- Creation date: 7/21/2020 12:11:48 AM Eastern Time -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2019-01-31"
  xmlns:acad="http://www.acadia-pharm.com/20200720"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.acadia-pharm.com/20200720"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2019-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2011-01-31" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="acad-20200720_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="acad-20200720_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.acadia-pharm.com//20200720/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>acad-20200720_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-5 Build:20200707.2 -->
<!-- Creation date: 7/21/2020 12:11:48 AM Eastern Time -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>acad-20200720_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-5 Build:20200707.2 -->
<!-- Creation date: 7/21/2020 12:11:49 AM Eastern Time -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.acadia-pharm.com//20200720/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="acad-20200720.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.acadia-pharm.com//20200720/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>d120197d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="acad-20200720.xsd" xlink:type="simple"/>
    <context id="duration_2020-07-20_to_2020-07-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070494</identifier>
        </entity>
        <period>
            <startDate>2020-07-20</startDate>
            <endDate>2020-07-20</endDate>
        </period>
    </context>
    <dei:EntityRegistrantName
      contextRef="duration_2020-07-20_to_2020-07-20"
      id="Hidden_dei_EntityRegistrantName">ACADIA PHARMACEUTICALS INC</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="duration_2020-07-20_to_2020-07-20">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2020-07-20_to_2020-07-20"
      id="Hidden_dei_EntityCentralIndexKey">0001070494</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2020-07-20_to_2020-07-20">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2020-07-20_to_2020-07-20">2020-07-20</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2020-07-20_to_2020-07-20">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2020-07-20_to_2020-07-20">000-50768</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2020-07-20_to_2020-07-20">06-1376651</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2020-07-20_to_2020-07-20">3611 Valley Centre Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2020-07-20_to_2020-07-20">Suite 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2020-07-20_to_2020-07-20">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2020-07-20_to_2020-07-20">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2020-07-20_to_2020-07-20">92130</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2020-07-20_to_2020-07-20">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2020-07-20_to_2020-07-20">558-2871</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2020-07-20_to_2020-07-20">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2020-07-20_to_2020-07-20">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2020-07-20_to_2020-07-20">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2020-07-20_to_2020-07-20">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2020-07-20_to_2020-07-20">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2020-07-20_to_2020-07-20">ACAD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2020-07-20_to_2020-07-20">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2020-07-20_to_2020-07-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139848143950360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jul. 20, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ACADIA PHARMACEUTICALS INC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001070494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul. 20,  2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-50768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">06-1376651<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3611 Valley Centre Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">558-2871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ACAD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=B'9.2-Y'.8SVW K"H-_H@FK&RJN$X3!9!:0^:?@^3$(IU^7LS!X6)#94XA
M=DK(#BX.7HD+S]P+NJF#P^W75&B&<'1+CNXEDQ4"B:("UD;,WLAGMJ\CPI5<
MU_7<OMNY[2!8O1*KAXJ5ZW:YSVI=AYL/KC\C$/T2HG\9Q)PI+FW\Q 2BL)8'
M5WJ/FA\^?&B(FT')-KC$;[,TDBJ3JHAFLC! 1T*9@S/!IS*N1<6%)U.$[K:D
MN[V$[IX+1I[R9,54'0BN >OINNOV>P.$QW.K/.A>0K2D;V06@T_YFD>'23O/
MUR#I]JZ]=K_7ZWH8X4FF]BXA#.)8,:VOWB_( _0C7]):5S9(MGN>1[Y1(=@Q
MPAF9**B2&&^5N#W___,N=[*6%Y=<Y!S6;]O% L2KRH!W41TH 4/;DHHLY:Z^
M\.%R"YJ2"6<;B<%5Z=_#\_>_X0ZA"W1S)5]Y&M6[&]<, PRMJ@C>126A1)M+
M;: T_,ZSLRFE0?'6]]JH3ZNRX.&)O?!A /O3\RBXP$^#[N!G#*4J#AZ>TQ]D
M!+,RW\H4RW$-(MWNX-H?]-$,4I4$#T_=WQ4WAJ4P-4F2I\?\IFNI<*&FS857
MU0$/3^(+*7C$#4\WY!$6N.)4U/+@*DT\?E4&?#QGSQ4KIH=!A!WV%[ -@PWH
ME_6ZWG\->HUD5?KW\5S]'[*9UCF0-0+BLHV )QOUAN3,HES9\//\%5ER(VK#
MKT'$CK#8J,CHY8ID5)%7*G)&?G1O[/Z19#!4O:4*1:XJ@(^G[*6BL5UZBWVR
MDK4+KT' '@$PDBK=^WAJ+B=O^A9M:;IA9\\D#4)/P6(2_(8Q57G>ORC/3Q.F
M-G:6?@$%L[6+,*-I[0&@0?#L6G-.#K#VSX!':M^HB6!K$')O^J"K#N?K0\/(
MK#C3KJ2!$W)QN644XL!V@.=K*<U[PQZ3RW\YQG\#4$L#!!0    ( /"!]%"#
MJ:4#U $  #(&   -    >&PO<W1Y;&5S+GAM;-55VXK40!#]E:8_P)Y$=D%)
M BHL""H+.P^^=I)*TM W.Y4QV:^W.YW;N RH#Z(ODSJGJD^=OD[6XR3AJ0-
M,BJI^YQVB/8M8WW5@>+]*V-!^TQCG.+HH6M9;QWPN@^#E&3IZ73/%!>:%ID>
MU(/"GE1FT)C3$V5%UAB],Z]I)'PI5T N7.;T Y>B=&*NY4K(*=)I("HCC2/H
MK4!.D\#TSS&=1!1<+CI*:.,"R6*'^%LNY3\E5M1[**3<#*8T$D5F.2(X_>#!
M7#R3+U)DB<^3]0Y;QZ<DO:/[@/GCFY3&U>"V-@E=J2*3T 0[3K1=^**Q+"01
MC?)!+7AK-)\]K".6P,M6(.53V,*OS97VV)"X%Q_KL TD3'4-O:$EC#(1!/VC
M6M0^R-[]D2RQXF+P_>!GHV?\;3 (CPX:,<YX;+;^M]23V^K<6CF]DZ+5"N+<
M?[EAD?%U'.F,$\^^6S@IE2? 47(!AZ(Z,M\=MV<8<3U-8W/;<_H?>OZ[Z]R"
M!L?ET;0_^O_R*O^.8[;<GL,5O;J@&TO"0YC3+^%]E;L'4@Y"HM +ZD1=@WYQ
M3[T\\M(_X%?ZOKZ&A@\2SULRIWO\&6HQJ#=;U6-8EZ5JCS^%]RBYGQON_Q+%
M#U!+ P04    " #P@?10EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y
M;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI
M0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:W
MO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:
M>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%B
MM/XU@LD/['X 4$L#!!0    ( /"!]% <.&7J/P$  #P"   /    >&PO=V]R
M:V)O;VLN>&ULC5'+;L) #/R5U7Y $U"+5$2XE#Z0JA:5BON2=8C%/B*O RU?
M7R=15*1>>O)Z;(UG9A?G2,=]C$?UY5U(A:Z9FWF6I;(&;])-;"#(I(KD#4M+
MARPU!,:F&H"]RZ9Y/LN\P:"7BY%K0]EU$QE*QA@$[( =PCG]SKM6G3#A'AWR
M=Z'[MP.M/ ;T> %;Z%RK5,?S2R2\Q,#&;4N*SA5Z,@QV0(SE'WC;B?PT^]0C
M;/8?1H04>I8+8864N-_H^8UH/($L#UW+\0D= ZT,PS/%ML%PZ&C$179EH\]A
MK$.(<_I/C+&JL(15+%L/@8<<"5PG,*0:FZ15,!X*/:XH$ZQZ#"PAJ748J&2W
M<RJGUW9PS2+W*D.:HPQH;0?AHUH+%0:P;W(@"2[)E1M27>EYIK=WDWM)J'7N
M0;#W\!J-'<V/'[?\ 5!+ P04    " #P@?10)!Z;HJT   #X 0  &@   'AL
M+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4 -5"I0P5,75@K
M+A %\R,2$L6N"K<OA0&0.G1ALIXM?^_)3I]H%'=NH+;S)$9K!LIDR^SO *1;
MM(HNSN,P3VH7K.)9A@:\TKUJ$)(HND'8,V2>[IFBG#S^0W1UW6E\./VR./ /
M,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6?;!/3K3G
M>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @ \('T4&60>9(9 0  SP,  !,
M  !;0V]N=&5N=%]4>7!E<UTN>&ULK9--3L,P$(6O$F5;)2XL6*"F&V +77 !
M8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5!TYB
M'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T<F^I>.EY&TWP39G
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M+GAM;%!+ 0(4 Q0    ( /"!]% :MW!T[@   "L"   1              "
M :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( /"!]%"97)PC$ 8
M )PG   3              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L!
M A0#%     @ \('T4(.95=E6!   \1   !@              ("!#0@  'AL
M+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( /"!]%"#J:4#U $
M #(&   -              "  9D,  !X;"]S='EL97,N>&UL4$L! A0#%
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K  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  !P3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d120197d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acadia-pharm.com//20200720/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d120197d8k.htm">d120197d8k.htm</File>
    <File>acad-20200720.xsd</File>
    <File>acad-20200720_lab.xml</File>
    <File>acad-20200720_pre.xml</File>
    <File>d120197dex991.htm</File>
    <File>d120197dex992.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d120197d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d120197d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "acad-20200720_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "acad-20200720_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "acad-20200720.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "acad",
   "nsuri": "http://www.acadia-pharm.com/20200720",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d120197d8k.htm",
      "contextRef": "duration_2020-07-20_to_2020-07-20",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.acadia-pharm.com//20200720/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d120197d8k.htm",
      "contextRef": "duration_2020-07-20_to_2020-07-20",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20200720/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20200720/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20200720/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20200720/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20200720/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20200720/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20200720/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20200720/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20200720/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20200720/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20200720/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20200720/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20200720/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20200720/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20200720/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20200720/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20200720/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20200720/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20200720/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20200720/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20200720/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20200720/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.acadia-pharm.com//20200720/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001193125-20-195481-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-20-195481-xbrl.zip
M4$L#!!0    ( /&!]%!G)5.S9 ,  #,,   1    86-A9"TR,#(P,#<R,"YX
M<V2]5M]OVS80?B_0_^&FIQ6H1,MIYEF(4Z1- P1(LL%-A[T5-$7;Q"A2):DD
M_N][I"1;=FS/3H;E)33OOKOO?E)G'Y\*"0_<6*'5*$J37@1<,9T+-1M%E8VI
M94)$'\_?OCG[)8[A\NKZ#F*8.U?:C)#'Q\<DGPIEM:P<6K )TP6!.&[U/]]_
M@[]JZQF,N>34<NCW^KWX%#Y50N:9_]$;] 9)OPLSG'I[D%/',QB0?DJ\(J3]
M+$VS#[_#Q2U\H=9QH^!>%+R+U>7"B-G<P:_L7? %EUHI+B5?P)505#%!)7QM
M*;^':\42N) 2QAYFD:?EYH'G26/UR>:997->T+=O #!ARF8*35;%*/*9:!+Q
M-#$RT69&<F>(6Y2<H%*,6MP(%G6@_XY[AL%*>(E= J?43@*HE6!^TF'<2^.3
MM(.CC.9KSOR%H'$YIZ8(Q:KSW^]U0#D72TP@9SE+9OJ!H&"[&Z\EM@>%UD\(
M=HC#O/,.1 KUSQZ$%T^P6;I.GD$>3P(@'0Z')$@W*.5N/8[&^BFIA1UM*]CV
MD%'@0TX[(5/GC)A4CE]I4USR*:TD^JG4CXI*,14\#UK8ZP57;DUG7<-1,^/N
MCA;<EI3QH\N$;;DM&ZB7DK]O;[Z&CHW./0 @-+$H2FT<U+U\HUF8L3U%\+_B
MMG:QOXK3/J8A06,1J*W,=Q0>R*N)M"WQ(B++?CJ8B-W5_?X0K\9@%X=]D_/B
M;&RN")^+H<]%^MM!N7BV8OX#)EK=O99,9T\>0VCKI/I#O!K9@\JS,>4O[Q%%
M!0NK>% ?/9'!$416^-=V2F?/^;J<[G6_N1@;K\$G54J[X*C+A):E4%/=7.&E
M'["LG;(QGT)8R!DUS&C)]Z]M4AI=<N,$/F.K0:T-S V?CB*_#^-V!WZ7=)+@
M#FQ5GCE8'WTO)@CA\F9%K\4ZX3SXQHO!R_%[@,JE:=^>H\ABWF5G=?S/X9:&
M'QLN0BR^/J%LNZ/^LZ-U=/#>SSUJ@#]\&U_O?[^6#QAQ]$DK72QJHI>:5?Z=
M;/]?J/R+0GJ+:^PN4P1J$0A\Z<:H_OT@]271EFK.\1M5A!9.>_X//V%;"]TC
M53G4YJ!C[XQL&MFT7UF>_Z'.PYE1R2JY3'P#;C3V 3=+=CARQ6PWKKEMB]:.
M,MF<Y>:F._/U5;US\.=/4$L#!!0    ( /&!]%"4H*GZB 8  $I'   5
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M:'HB,^GI2LL[["RWQG/XDQSW[**_'4U+:@X@K&\!_59/FX@ Z-3/7BN8;+V
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M*X=L4@_6\-"A>,"F9E7K-KEKW?S2NLEYZ[:\](@JUGI7EZM-0=)POW-^&6'
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MI*&R-^6V2!% 27!5CE0V)3\@A_00;XI#%DY?330V))YN(\!NV+64; ,N @M
MZS=;K7FJEI<BE2?&5V,%^"%Y;QQ=KP_+9LB$/)<#+%6;2G]W6NVMPH0^&'$2
M:ODQD/*<W;BLJCC1.$Z@X'C%$2;^EDT2DX\GM&>,H7J*K( U\-#K @S^RX!*
M ",3(RZ\S RQB6#(=FE;UWK]OR&8<8FPY27!_QS$$()IH.;W3(5WMHPNQ?!&
MC2&MJ#%4H%;MR>!63E/*F!U\OA*#_M^Q^>LKQ2LY%[?WEUW^WXKXM=^[_OQQ
MI=UJ?2BCQN.3\^N3JS]BHHX"V4H8>UR$L;^Z,+;/T,ENXA-QZM9+D./"3 XK
M2/YALZ'RGDG@RPCRY3$COQM-%Q^+OA\-N:UA67P!O!5% Q3VI*GUFP  '.U8
M&[B\](@5?-),[FQN-K;6=QH;.YV6,XV%A22=@*\#=M# IC!%59W'O6,925_R
M"I^<YLD!&QOKC9WM[<9&:VO['CHT2:951!DP8Q!"+"_5$E4P*X9">C"1 F'$
MUN;N-GPH8CP5J'@"/TMF-@#S76BWR.00MZI,+JP&Y2*<']MVV8<[_'^"N<4J
MGC%XM]%I;6Y5E^T6NL#YY:6797UKH[&YOMU8!^^?RWKQ..?O$V36'D8S%)D[
ME0C(E4&+YP-GW 7,40 IM[>W3>E)<+P14Y*G"6=:+]BAHQN59@;4I,HK@YPB
M^)>)-]$W-KX":L[A80/1S<=YFLTGE!YUH3LO9,ZZ0Y-G):!]"Z-5S,5NNX34
M%O;XR@6^0+$N1K0)AQ)6$B<=FB$L7/6QKYMLDEYB4J)XF!CI5^,QHF,.JQ$1
MH8$402B _(4'K:1 )YA68J0T'V;3&*S!XWX95#)P@P[O/0@ZZ[/1/-FINH6-
M, R>'T:)Q3-U<2-3#Y0GE4M@RO(2(&&4(8JGK GTJ9R$07>2A_0JD_C0,39@
M' ^!]/7=3F7U)- J<I#>:4,1)''B JH * G,0%$L/;^]T=P44R5=XD4"\&/0
M&1C6.+-9RP&GP4Z^0YP</JJ=G0U.5@64.^%WM+>:VU:W%P.#.1I8XFR*P90!
ME8YLH.6;?!@ R6"KL+F0)\J[5E"P]7 T\J^2DA*@3@-.>7D"0^'0OZC&6\VG
M+>"UB1N83Q56K0B9F(VS>5VB\=A)D;A.-"63R3HMRDC/;7?M^)IRRV<V+4)<
MZ"E/A0X [KY1<#T7)A=!">WQDYQI=QJW2GTK&&-B%34".50!Y<.&.M"_6TEP
M&^7GE/ES$>.\+BYJ]/)2)7Y68\C:S%SP W,F97U#A(A^.%$BL<XF(!YO1H4B
M2T.=<G6S.![\^X=)-*Q4;:O=W/FP2G*J@%,UI(QT_Q_0*GBK\X_KF^W5(LK%
M#:Q/LP$LJ:*X%\8*W@KOPUR2!.)7<$?L./")/]L=_IN!LDO=524:JV8JJ: 0
M!.:VJ-C>LXP9^R:&Z7IRLR"I#;(2G TLMJPDEJWRW<6PC(.$"-H2^2:$6)'%
M@&8^I(T.(EEAPCA*'N@H5RX],+=OOB$EX-U;7J),6(OV$2_"-DY7"22FV&QO
M,I\O(0Z.F#\NE9W'=+NS)4@84WK,>FMY?S[&># '8/]"[/=08LBB A@98(4X
MGBGZLQC.B=$9NQD,Z1"OE,&4:!D1'+N3E?DG<U'B#YF*>G4;=B>"OU5!@/<'
ME.N@2@]E11B=0"HH80W-;8"]L"(.SN2V4&>SNW-\KE@=EU%?#-PE]HJ0 ^>)
M/8-M<:]"? $GF>;)S">10[3^D/.SK-H1%8'QXQ9 5'$.G4S0]XS2#0E6[,.5
MI-,P!F]2>JM8?.G)_-B!'2NNK.@,X(H4D,"36U@[&5P-&MU9@LN2>8^4E-;U
M'O6O"ZCE\A(QGB&3]*E8 ];?S)"'&8*W7+7::#=;'^: &3F+*O]I0]:WFEL?
M^$XQ/_RG,RL.+^H'"<+F,I"XCQ"0"@C?W/U@8]4[\]*T?*>8]ZI8%@TR>;KP
M5L0;]%H.4OC=&W I!6USKQ\C/HQGDQ1#G!;RW::XB @02LC8K84X-O.M'W!M
M+F7VV#/WT.!\\@/<HZVF($F/)0=*OH+]"MGS14I39&1GP\IY.HO&G7=PRI7D
MX_=,UK\<^CW:/O0&*:P?J)/! BK?Q@,I5YP0I3/NJP*].F? (EMK*"PI1PHC
M"%1N(P9K6;D$7QA64?,F,AHKUOD07C*9UBD@]#3%BHU0<L6>P6?&L18<\#B'
MS-2%RKSFJD/O#FZ/\LASF0D-.Z<3(JXIJM5#255[/8(2E&$DT&@>(<0*II:T
M<A4,; EAC#(@)G!LC-E2[4*/NTEX4!#Q8IL_6'];M]6WY258XJ)@8\$6LXGR
M^]8IE6$HK3<((LI/40&9X]X\XE(Z1[R!DJRX3"0#!OBX1'L5WU-&O0O1>GT6
MJEL/6MFAH9K(&VV2-X !_8P+LS!6H;5"!)KNU%:[",,(-@'4P[*O._=C!7A.
M0%<?+;\^EJ_@O2S3JC]6344\!G=2\+Q(+(X2]5NN'!1-X6P2*U%T.U% LP[C
M<!:X.T\<,<57([;9G,KATC.W(B"J_::JRV26,3RV81D9'@@[T BE\"BJTV$>
MY&E1!0=@X0I_+54*D&>B@!VAC2,59'6146X:3IX&*7^U(NP@L6#6'>I&\)Z0
MVI'^3@@'H9@:6;(T^9?4!#E;(.Y!\Q&EP-; ^U*;@Z<*Q\/U2D#XF2+?DRAR
MRR0K0IT1=Y(\57E_9I)G>>EELCSB@21/4PP<[O (-I)(4,,O-$R!5; XB]AT
MMMH[A<K9A&D.HV7!@K*R;8BMF%?ZH4Z=7H,9B6VI(J$)],386"\"$\&BY:6)
M"1V"";FQ8<2EB9D1M*9S?IVSEQ91"^SY4/L4D+-\4V<0#/GT!\WCQG.:$UXV
M-3L7A!0>^7Y@\"(.>6X^=E.I"ES='1=-9B+*F5&.FP"J'!MJ2+3)NR@K?L8N
M#>\ZLS*J0F?/JDUL-CY?%]G^P9>CYVV.7>W*8:=+&U1T9L*"P1Z9)"W,7WF!
MT0.9H?$D<P$("4:E9RPQ%G@LNBU @ED>%$[R1F>)J2]D'\H8F^"LX>(T<(2D
MU,^0FN4(2" BCT@<*0[P34S9325J,]/0ZZS"\(&7?*<NPCSU9$(I0 [QI)^0
MNQ_#D5:6>2=B+>OB+Y <?[KH742.=UM7Q4+G*LCC9C1;H&?0X\B3/@)I"97_
MU[M1FZY\0_DV;A3CAKIJ1VP$N:<X@OAT3T?L\M++%A@>Z[;"Q+_DD:IVY[46
MNO/NZ?'-BI8/ND:E_KG^P,?Z_LKV">W2#Q5)>;P+LP(-B\Y2ZVUO5&!BHFJ.
M:_C'<$!W!P&6 #=]PU+7 ZW9;UBN9Z,ZU":>(Z%HM<0KO)P\EW&I!\O6L$!I
M5%,"T*)2[^]EX*"CR-Q8Z!\J7T,<,3,G)WSRD5 P2D+R+99ZY;/GIDY!X !J
MXTENR/VG4_C6^5*/I9GDSU'B^H6J=+@,X4*#34')"QJA9[5!S==LJ_Q3(U"0
ML?4'F)SQ^8Z65WK5'I%:0-'$$,3,J/&"GKM2608F1GX"T%)W3E$ O0;3!BSY
M6%7,>&FW+921(6D[M<KRCD'O>%V,VO*$%4A7VDMD59A=+\;(Y-Q,NR<.OAS>
M5Z$^6/MRV*1LR:OKVB?;H=TX-8;C9@[:0T:);X!A*K-Q[J#@ZO)2P59&_D63
M<4K[2NEN<K<F81TI@PH>Y1K.&X%;3EI.4$96U2FYT%47PWPV1Z!#;5-8]>K8
M2F9K/DW( 5795#W?JV9+C2]3UZ[;!';1=4PMQU"S!U&]U6Z6QLHJYKCYGI'[
MYX06D<Y,_$;2NU>VB,EL7"'/L*YV\X?2V3$N/W'5NV(HJ"S(VUL1%:!W$U#V
M"&$65X6IKH-(R=ZE@T@)U2$IT=6DDP0Y2'();I.4=6K*$OAZ!*"_O$2ID<2"
M?=<V324X6+9_6,'BU#?W;'!86%F2RZ/?2!N!TLJ!9:M1<E%]NH<ZC)HHMV:+
MY"KVWAE@]CXRN-][$DY-J-:B$3"7T63&?)_)>DF4/?XC.+KADSKSSD9&4<YG
M("B,H!W!R\-GE+M;C;]66YMHP=030:5"Y9>U>X?@VG4NX@M7D*)_SU,!N)NZ
MO(Z%B96^E %E=3B#R<L[^6YS:O8L!:^_*;Z:G 7-DSFQB(.8K*S3$%K/%9M2
M38=I'%!)'[.218]\&D.9K0#+M*CH,DJE730CYP+=Q(240HH'9O$!M?[ ]B5#
MZS9OM#5X[DV7B;ZAEU46>:JYQD!ONR(;$O)A26H:V=W=A&R#?P^3S5SX#3MJ
M#[JX7A$ZO\(%/T1O'/#,**;R;ODX,]AY:%Y!)K\I MO"#(."*&Y%P3(45Y=M
MOV9V%P;PL!'%X14]]'3BY2&=$*)LC1QECDD5AM)9#T(9-@_S6ZY=?2^0MV^1
MQ#@Z[)<1]<!V;?47;%/?'AY;/*>]>)+PB:/,+P(;B-P9-<6,KXA3JC'8XX?H
MX!Q>&B:_.@I\8O/?:$=_[5Z=]\]_WA/]\^.KD^[@I"?.+JZN@0>NO^*:.#GM
MG5R=?A67W>L^P,$ L.'ZL^B=G.%'O]NX.CGM7N.9R\'7X\\7@_[@7KIG1!'9
M"\C@SB)67'Z*=X ^9-$].CTI7G5T<06"&L RI]W+P<E>\<>C*UUDRXJPK_FX
MTEH1QR>GIY?=7@]<*'\/+KO'Q>\J3K+T7%E$)3Z*E0H&@T ASMF3-T;[;F"O
M>'CCPVQ1U[V[-\7?' "C'$T!QBRHHH/4D-+=?<O8.T^W%YZ^9Y[J^^;'DH#/
MW75<%O-[)!X6M6<RG+_:$7#M[HD.M$K.QYV1*WHC,VUO90@."<M8_R.Y5'(G
MHTV@7F:39BF/S!#\WQ7]'TE45;O?!?1=0(\.'\OYW4W,/%N,\VB^0>-5G-6[
MD#\MY.N/RG$AQ/_! GS,!5A=@K0]DHNY5+97'6'CSGDYEB[+P[$H?DQCJF-%
MW"A)]1@PV7/(?"']3W&B#6&IFY/2M8B-. 5T)=-)7>1<C$B*&F3Q(EM4Q9QE
MBS$"+FT4%$J*FFJ.FW7,%8T1!J<4SR$$J3MHST5:'ECGHS_4($K?B*)N"SN)
M/TWC2,G52JVVZ,VR".^NPKSCEO\FC?E5)A%G $A:+A/E M5TCTWJ_UX#DB-L
MI/3(96("B&$!SM]%Y_40Q7^Z7)4&-[8R8\]70YBT$R9;N,QMEW@Y.IT4WY!A
MAMYGG;]%YC:B-\45:>06?FZ"#H=%\Q&/MLDY"Y7MDY2DLD]6R:GD$H\#P _+
MU7:7,;=,DLDTFX3:XZ1*9<#ZXGW899MZ7 #KMK"651K5*L.&FL:D[^;X7:>>
MI5-.2XH3J0^JRAR0 >[PM?1$*:S2]O07"6*K*7,)0_=-'TKB%\'EW#D/[@6W
M)UHXRXLK)DDI'>LK^ST?FT->H],TN>^KR+9L5S/WKM]0DI(,$^E/+9UU@EWF
MFPP4""6EHY^A' /7T!5W7((/P-F9@:#&*N+>L:IA*,B<LSP/JMF?M"+UY]#\
M/ST0Z[H3'5=%6& 1&/PD;O*?[K1P<?2CC!]PGZ3WZ+ V5TBBOQN?NF?]TZ][
M@Z]G1Q>GS*=MXA.7DCH?YC/JI%1CSCA1L"_+8R^K?&BEH()Z=F/Z*(F+/$1M
M^X.X247GPVI=1!(^O;RT09?H.#T']MS&2Y6'VA;?7:>[\QW#M<W9'0J*X$/=
MC8W9#293ZHP[[;(\&7*1J=;A$3\%V7[[P^I#6OZ>#'BN1OUYDEK<7LA1S)QB
MO:.M=[3UL-P<&SG?D,J0"K\H<CC^>KG>W:#6 H!W;A=V:9IO*C.P6_)W$ZC5
M$C6E,Q.KOL<FY9,(5WQRMKP#8V9L&;?-1Y&I%$P9)6Z8('P6X28U"&=SI\W?
MK=R[#/]S,@S''QJ?#RK/Y)E$,DG=J>Y[Q;9+/";?##"BN7)K@_CEI6>\E^<O
M7OH,X7V-DG//I/QU$6J]F.?.6]2;KQ0W&''7#BG\GON"A"?C- _4O-K/%+U>
M'HK*M"/W#<ZU5=/F\@9T\ $%&*,YFFWFL+!:9*'2MSAZ7_192==:G"../?AR
MZ#YX.Z3@LM),0(VME; 3<G!DZ)R7*_[3UK_-F9VKXNM3]_:YOEOKQS'I#WXK
MUI[R^%'C_,/V^'G;OR\65G-)B43<$$>G=$184&[BTGTJV%,+GWVZ>\#9?M*T
MR]^S[JF0.L3C"><@21_/^("R/0E/'=W]PW/J4U<Q6!]J$YCQE.3O&1\A>G)
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M4=VOG+(GF+SCC\IL^X9'-O_MA&[:,8O6[&_#VI[C_WB!_\,L_SOP1^WXB 6
M#00U<:6:Z)PU%9[@W:,I&TEO""\#ZC](YMCP#,[58K9,AJXH#6$DVV*!"S,8
MRM((2!=*UX7[\24.T$[,.1Q1)\8(P]',8A$?BWA&FQU+5X1\Z+@.? %\%F1%
M 8_@GF*!SWDR3GD2Q81'3&G/F=(V3+E]W6KME(E%TF68\6G<= K<G45.Q![X
M&O(5QH%OQ CX2=B&R,!,*+$DLWG,6>(377#-8Z"&?*"_A+"'?'0W%\2?6HTR
M>W/$OJ*$4)! *I%L?HY2U<,2?.D9&EWB!&-XMQ&@$K:UIZ#1ASFL\<;MR\9U
MJU0]W#'OC&6,DQ_)$/9XROV)4.0= JR1"7!+'H2X8_OEO(+9JS-O8K$) ,:'
M]8Y$R>9 /H4VMA1L\"J@F&_ST(9[8D=#CN.E*> WF!%I>!3)D<-C -N#$T\9
M9YZ 5X;"3N"-L'P ^'&Y4BS +)Y=L%[OTN5*+^ A<J9D1^4J\8+FPU6KV X^
M5LJUXX,=!;WE]M7K(*\K(X=&-R+H :1\L2"'L 7W,'$-LSLQ8Y$ T6%GP6;1
MM29L(N'SLRN'\$_',] QLK0/2 Y1;CP/GN;G3JF?0H>H:,'VC&@,!PD61?!R
MH^VYD9(P4OW@-())ZJ'@HIUBF&W[TG- A#"D;*5>VWD'IL8I'9[^"JQJB GK
MD#X(L1AG[P"9Y+TP*\D(QVCF!3!DQ. R""S4FX32G,@=)D#^Q =$Q8D/2'9G
M:C=".4Q )P>+^THL)Y-0[T&QL&(7M)(I5=-]4-H&H$'"*12!"SL.[&/A(H].
M04J#W.J+$'B[#_QW)^^=D:5UJ-F:+DR%M%.9:=),'1 H,.EH/DU;T@A1$@2P
M,BWB)+(E_CNF!R0+DC!*!-!S&$IN9YD(U E#L0ZS@WVW8,Y .[!74.LY?H)/
M@YY"9?([#:V4 2DX^#!6&B%#+<%#UX%=2.F9 951GQRY1@.3^>([3#\6051F
M#1@8MC:)T"+2!D4,$O!.K4LA-Z)]<T)&.*+WZ=DX_KT T3_AL0QAB"FLFX>@
M"IR ))>C6'/1:*>]*NM]>7.0=]0D:% KCU 4M!/A@]1U702/ZY:4$4%B=RI0
M^-E*-HKOJ.- QRR7V9:R!!R8 @\9OB BYK>!/V#MP/*^EEPIKQ4+0Q&#5O'S
M<]K>!S'\88?>9P3Q]GZ]?/AAM:P]>A6[M'/>&,HD7KIMRM=ZQCX^>"UC8REH
M&)A77)MAW*C!9T6V$18U(RR0MFL_M6>9Q\AP*19H%V%MT^??<5!"LR%] 3 '
M($VX)5N@I03"":#BVR#X?\>_G[.&+>:!!')*RNU)F=N\C&"J[&21LY*S5NHR
MNWB9@H=+AON5: >Q!4L'#I]RN!'4'.R +7ZCP8 9 E ;8BWC!E\F'/P(6PGV
ME5!#PW0DF'4.VCA)$/,[E"Y39^B :&';_7ZOL\.D>L3<Z(/J#< \"Z8A&FE+
MG[N!YT#,:9L'5I_Q6S1#SK< YQ^*D:#Y.-_)YD,^!FL#-BY#G>PBR 9\1->Y
M&6618<C(,+20KB!3',(NC*;DJO0G\K%L43['8_,9MFRID:H-H3]A#:8FQVZK
M\PMPN8ZR%0N,_G\6P.[.7)$7/,)[Q/#X5< G &6@V%UI*, &$"?<?>"S",-Q
M9Y<]UN_\"^:WMV5>28&^DW\<T_^VV*^=UN#RXU:U4OF0NOO-]LV@W?L1HX!/
MAZ9TW.SDN=C.J\C-MF'XAO%%%Q3&_&TXW@(1'HV^I8,/]!(,VC8NKMKF51>W
MO5:[5X)MNVIT^^T3\\?**2ZN9XNIUWS<JFRQ9OOJJMMHM3HWG]//_6ZC:3YG
M(:'FTU/@81_95@9NCH]&W F_EXZM;VR9A^L?YHL:M!Y?9+]HK %14MPI_*"]
M<KSLL>K"8TL&R+XH?R]N3NZJ)B_+;PY[&AQK4OJ\_Y2?GG'F[:><]I.7BI5B
M8<%%)'+ ?WKX'P32!I<;7.)>/O+OLY[]<J]^#322EVY4G/&MBX6\<[W!Y :3
M+\?DSQS,<2#<'6=]5Y %"EZUBCUN_]SO[^C06CZB4]E_$G19DV"#NK\OZDR8
MTIU1L!<\@G$"NEJ@VT@. YK^R[2U)$?DL9R,UD'<JP<1^O.4S"";DMG8HAND
M&UOT)8$R]N(X&7JP&^V^0=\3Z&ODP18*#.2K</4$0SR8TIARG^U_H+"."1;)
M!00B\G+W&Q@2>FV'A^%4<*M8L$$D>S+!+!X\ M_9(,#%Q@3=@'0%2%M.I#-"
MI/LC9E-J:*FDK('4H\PM1:4?@53C<F-^;A"W"G&#!\FB9/AO,0)< 70$2"D4
M@!0/>@)3( !E$F1D*-XA,9V8A^EVO]&.5!4-?(D?=![%%L(3JJ!$%6F%PJ7T
MFPJ.FYJ3,)FPX>QQSG$C1#>07@5IP$LFO94 ]A83-::<27GZB/O1W V;QTEC
MN'&LZPN).^Z=6 =2(PO<M9@/I>N,B@5TUN C@!]S0.)[C%DO^,JQ\793-Y$M
MNWE&/+]E;8W.^ >AN$>N=3,U@NSLZSG,S(_.=K]BDL@4OU'QWPLJ-/Y@TM4\
M9;(J2PH!@V6EODN3F5ATVVJ90JH_5IN7*7/3Y1F87T$*J3P=5C8N3A84^,A-
M;%/#%;E8)([>/8:'E(E9^0#>.J9W/2H[>?-BJC3S.:4=#5Q!PC:3<,]4T@B8
ML#-T54E*IK+#%':8O.6S%-VO42+<T%(&PB^Y?"A<9!#AI[4JLT<Y;!?&* $W
M>2^J]'Q9X1WQ,P!D=<75ZQ=8K,T-:973^Y5@O'QN5+6H452SUJCKK.2+(UY4
M"5$L9$LAUABM5H+-GZ3ES)'X+<$J9(S.ZJ(,+9.="+"H2BK :NDV6SL&F5,>
MI]A4+*,@:>7PJ"J!TM*+171NZW*!M"1@9U69Y:HJ#'M%$09'J"/CVE*IO)=5
M96"UA2JVP/J)<J8]@(H/I(_5;LIA'L%^@.HS 4I\#5+FFL/[1U-0N#%,_;.J
ML6*7,@I(;:8%F8/0P9KU&P'B,[Q31L1/W M.6<<'81LG,=::V,5"IDBC5CF<
M4X6/0AE%K':8JFTDA. A5IT3."(CK;Z6^V75%<"CC.R#J[5*]>CM9:\N1(MQ
MR0N%:& P+*^5'LZ*A8P1 KJ#*H!-'?QK5?ZF 31*5>P=@Z5^N[JL-F]#"0^0
M%ZNZN8RB7+"@TN+EI?:/V:;^5(@IUNJ#!VQDO$JNZ+2*2J?488Y+2X,9 $K.
M@X=H&&#)K?]TE!Q&1C6]-E%SN<7<I(YVTM+(G_O]W+5:]3TJ>C7&4IFF!1DZ
M9U1DW$<AR*H[RJ\# P8EG*F-Q,*D1;L*]L=( Y0%J< @(B]!IK#7,0X78$ET
M6@X*3=C*W@LA2?-["URR9V&IHL^;*JH_:1W=HI%X149B4X+%/ 1'K<O#.W!U
MI6\JMF$S!!H<R'7SAI!W+575'3]\C3Z,H[S%,S>#US!@(F!-,(EXZ.5=HYK6
MS/D.J6)AW>+/U/)0=D->]=-?:-8!'TG#^E3"J,0MJGN*.3[:&#NS,;DNAX_U
MPYTGM?!QF2V4:QL]3S:1<:1RBT!+*,/-Q4*N;6%Y.9/UY[6GJL#$-H?%)J$C
MD 4_N?$IR:WJCJ6=OXS R<XPPLP6D ++^&>J4!_>4<N_HTPM*YE>C 49BY]*
MGQK7G:MO)_UOUQ>W5Q2[.<38#<T=_<P_7Q]*>Y9J5EC[ <POGR0!&UD102^[
M7B_7\W>$&%=$F(;"<Q0JUN[8,G-:;_D'>V;YA^_0I]309;W* LTV2X.$4#P:
M3>4#N0Y I2<YYGG(%POC3*^B7*;L%GB G*4 ==42ZR>K\PR8K5>QB3((3NVB
M?O.VVRCI1BRJGV'_3#BITTB5T.2!_QXN>:9UN&E:AW_5K<,=;&#RE'MC%,IR
M&+V*/M$1.>P(*A9P#\%;HY:',$ G2[ DL/&?>X=:M59T/*]L<S;]K/D7@'#"
M$#P?C0!8F'C';D_8FW5"/,\KO_W]TL'>4:E^A&W,!!2#%VHZ-.$E@"1U-:8N
M&UQL<O!S^7HAQ&=OJ-?W2D>'AZ5ZY>!PR40<M(94=PEWB2[H0VZ'PI J -]V
M)&%;JO6C@_WC0]5?(%P13"6U(8#A.#.)DT42>W I2^)X&LID,BT6L/-;]WH?
MJE[O%Y$?J9N7CBMO/B[5*OL'V66;A3Y)^36:QI\G?:5>VM\[+.T![5^)],MP
M3/UT)!2!U(8C7'04@8GS+7]P%7Q(D'</#P]E/N) \%* '?5E$(N6I@;B$9-.
MV.06"=5_2\R&X^!NAJ#1[E50" 1?XL>.RQK))(GB?/O^.W9PK3IEXNW-XL8(
M));2'BJ/=V-V=1[7P:@\Z">,"PGNQE.+@O1\/*8$) ] ^GT'K8>-HZQZJ @)
MH[E$?66 FNU!M)[UOR[)^1WM?SAE]R(DOZ]$KLP)):&J9[OPP+DV4_*CU<K[
M2X?+:>1LP$Y9QB^=0LW:4Y-0/:&JM<W7S4%@8(9\!/Q ,2\4!8_;;XN%*!E-
ME86N+\.]GI2V,N%=#(T!F8FO +^J*PFLC"0DTU4WJ^,B8%#803H)(4U.8$J#
M6J L99<B4T5H6G 'S05J4 ?718Y&2:"WU\(A5* %[I-AC.;NF.B$+5N3,A[3
M@44-"(V,!0.N##"2\#/MQS S$'UWAMRZT@8<&[A%>LZ(#1. LZ\W<.I,<%!2
MD;#B*2%JQ)$;@1F=WWG*M"9,@0%'T[F+ZW_Q]M7UYJ$$HN,C3#9"2#2U,$H;
M)9@S5'8@[K'N'5:A6NP*5K%;E_(>CN]00'IYB!9[T-!&3-N$=3T(YGTQW$Q,
M@[$NY>IAZ@ED:?321>U;!WI9[R:I<B<JO(=PR@U(;+>L#1%%/E8P\ E\!-Y!
M[,!^F(^!UDJX9;A_,"<1KY<,*UT.C/+K?[V8NS&KMT<M%Z1& S?HXIPZ%0-5
M!$$!^G3FT0P8R,.5Q5,T+F(=S9I1QB!ERU"Z) 5\D80RB&:@PW@< F.9HT\B
M\L:!-4*Y*N#K2Q*? J0!IAR&^LP2$.2(Z!D)%5L&L!E@'6VG?D6QT*J!<PS>
M44R7L+L5/( 0H_@D1K@=8MY@ C/*++6[V,!-HMM$>E6 /9/WG<+N8+Q<%U&I
M<(2;1.K3PB$;3_MD2!V)"5]=A$+FT2<4M!1YPO*4A@VK<(@H*&I@=HT@!#N@
M5JD>@$E@4Y4@Z"JX 3C6YQXHQ:_=J\:_.JT7\NA/H9B<*BXMFZ;]*!EZ3AS3
M$0YX-(%+OA]($Q]P3^4S0"=7'SK MJ.;5F-'V=W+LNA_G(0VC0M&E*GC24D'
M LQG7Q+?'!1D;9I-_Z#\*A:4+3E0I_^0\D2'(H@U%XP=USCNN-'T7:O7-040
MW=;73PUF:U5)*$WW!-Y<+:? 1!E"#0=9'GMZBTE>F/9F<[@&OL,6]\*5 7%]
M#G".2<L\$D*I)12]H]'\Q)%:[V(QI\3B($)ED)N"BM'X*$M'231O_-!T)4Y%
MOH3;/!&B668L'K+^?'G/2;MYP@8?VX>1J9+41AL#9!.F'^D2R0MADV&-V=,0
MBUU !M]C29]6*QGMH.>,^-,S$?:C>0AS<$FHE:CTJ<%%S>1]Q7=YP?O+T@]L
M*%",\%8\72A#YT<"DL\#?2M0:\%")&A @<8</=<3<0Q$]&VP!H6E[0D5]U7%
M"1D%F&H\M% G(?>0V['>B'8,&"\-KH^34)G;F3@5SX)9!W7&,L$!L7?RZ_DR
M9[>,A5XJ=_7&O/9)A@\\M$M74M[1L5TQ[*%',<]WB+!E1B/WT5"U6#!DI?@L
MUR<)1;BOZ(R@H0(V/O((&DT\1B<*[QKKY;AZ.5$Z@*EWC;)#4D68A:<CI6.X
M#NAN"L!:V7L72F$#&>N2E2'816.LPUNW]FGE"7?D62@IK'F>/<7R63\P/Z6T
M47(\+\2(57''XB13F3\_!6D9I9 X)"I@PG"?$@ 8GR:N'"5AJ"ID,K#'PIOO
M 5CR&7$!9KQT\<02YB?>$$:%Z81.=!>IF!;6.H(Y#!XR^+\@'D9Q C/75<M
M%[,NC-NI"E"&08)06?TZP(]%-L"G6#FM\B(HJK'J!KWSS)*TRW;/58WT&#QO
ML&D78^WI[%AN<GBLB=!K5A9=1GI96HYR=[D>L.8'2,&@8(0BQ ,,BZW8.%PS
MPG,HTJVZ)Y-AG!#XZ3;S C2',>: +FJBG'H5 M5R2FUYNN1 L1HY44B3O%SF
MOI_0J^F(+7@5O-M;JZ3LYVP\$=<[ P&+R0X\<*D%0A4QH*V=JD4YQRRH\],
MHUH7BFF3*II7./4%0%!%37!Y[>\Z(]@$TJNT5IE]DPG!>,03W(1YG3N5%J!3
MD%#!NY,Y+S%:)5 L?7AB%("IJ[B#1R;43 8=0D2.M;;0XQ8+#FZF+>9N"(4)
M0+N&0Z5B[AVE4O6KNJ%SCV_++/+*H9I[W-<>FM@>\@K>7ST^WE<'B3T];Z+"
M;YCFP9):';9S<%]B)\1P!;E5\QEC@BI]FNBKE1DM  _Y0;N4R:%KYD0G]\ J
M!#*MRI$@RA^I3+IOC-Y^ALE'3CA*/*R1P^)N/HXUD3(4M4"RH$9&>H> "8J
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MG2\??'Q3D$$C19VI@7!^F#?=K0*%RFY73V+ 3#V9G4XF:MITP?Q05*TVR '
MLW=F\=1S1A3@R=RPMW@=Y+(*LBYX#BHAIG,Y%%3-W#9T\)ZUSE?;\-2&IPR7
MF)K4)UDE9\B W6$[?,12L/)\)9[.V62#ESJRCY%[X^FF.043W,5ZO5!5R^(W
M,HPP-&QC-@=YB[3*+E:2);8ML-:'8VWFG-MT]2%')AF&W)ZI>5IH=LD[[@J8
M*#(=?O3X!.P:_$;Q$ 9CS<A@04V$3_W 6<%@IIF3/!LVVU@]YMBVGK'!E;D#
M2NF,',F+<TQ[4;6NNC$UUN$ZQG NSK=S*:1GNZ9JZE2ME(N?.O%MAQJ/S2S
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M A/%:/-E3JAJ!TX$]A[U('#6E%,J=!ZS](!6*BWG[&N_6&BFU=R8R'"\B+4
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M$RY'VG(OZFSWXK;U#;Z\'%Q?G?\?4$L! A0#%     @ \8'T4&<E4[-D P
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M-V0X:RYH=&U02P$"% ,4    " #Q@?10BN]3]O 9  #0<0  $0
M    @ &<)@  9#$R,#$Y-V1E>#DY,2YH=&U02P$"% ,4    " #Q@?10IA=X
MP54<  #XD@  $0              @ &[0   9#$R,#$Y-V1E>#DY,BYH=&U0
52P4&      8 !@!_ 0  /UT

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
